GH · Guardant Health, Inc.
$163.38
+3.26 (+2.04%)
At close · Aug 19
Market Cap
$21.92B
Shares
134.20M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$160.12
Open$160.72
Day$158.81–164.26
52W close$54.79–170.77
Avg vol 30d2.2M
Short int11.4M · 8.5% float · 5.4d
Short vol62%
Last earningsJul 30, 2026
DataJan 2020–Aug 2026
Filing10-Q · Jul 30
Up next
Next earnings call
Oct 26, 2026
Est · unconfirmed
· in 10 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Jul 30, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.64
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+42%
above
Price vs 50-day avg
+6%
above
RSI (14)
54
neutral
MACD trend
Negative
52-week position
91%
near high
Momentum
relative strength
1-month return
+5%
trailing
6-month return
+68%
trailing
YTD return
+57%
this year
Relative strength
+57%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $151 › 200d $113 — 50d above 200d
Institutional flow
Accumulating
+21% holders QoQ · +155 funds added
Insider flow
Distributing
Net -$39.3M over 90 days · 89% sells
Short interest
Falling
8.51% of float · ▼ -0.0% MoM · 5.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
597 holders — near 3-yr high, broad support
Squeeze score
73
high risk · 0–100
Fundamentals
Revenue growth
+33%
Y/Y
EPS growth
+7%
Y/Y
Free cash flow
$-233.1M
Balance sheet
$1.1B
net debt
Quant / Vol
risk profile
Volatility
58%
annualized · 1-yr
Max drawdown
−33%
past year
ATR
4.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Jul 30, 2026
full year 2026
Full year 2026 revenue
Initiated
$1.34B – $1.36B
prior FY $982.02M
midpoint +37.5% Y/Y
Full year 2026 non-GAAP gross margin
Non-GAAP
Initiated
64% – 65%
Total non-GAAP operating expenses
Non-GAAP
Initiated
$1.08B – $1.1B
Full-year free cash flow burn
Initiated
$195M – $205M
Non-GAAP gross margin
Non-GAAP
Initiated
64% – 65%
2026
Screening revenue
$218M – $230M
Prior guidance
period ended
· from the 8-K filed Oct 29, 2025
Oncology revenue
· full year 2025
25%
Non-GAAP gross margin
· full year 2025
64% – 65%
Guided vs delivered
· last 2 settled
Full-year 2024 revenue
full year 2024
guided $655M – $670M
$739.02M
Beat +11.5%
Revenue
full year 2023
guided $553M – $556M
$563.95M
Beat +1.7%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+42%
Bullish
Price vs 50-day avg
+6%
Bullish
RSI (14)
54
Neutral
MACD trend
Negative
Bearish
52-week position
91%
Bullish
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $151 › 200d $113 — 50d above 200d
Institutional flow
Accumulating
+21% holders QoQ · +155 funds added
Insider flow
Distributing
Net -$39.3M over 90 days · 89% sells
Short interest
Falling
8.51% of float · ▼ -0.0% MoM · 5.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
597 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $55
Now $160 · 91%
Range high $171
vs 200-day avg +42%
vs 50-day avg +6%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA loss non-GAAP | $55.9M | Q2 FY2026 | — |
|
|
|||
| Free cash flow non-GAAP | -$69.5M | Q2 FY2026 | — |
|
|
|||
GAAP → non-GAAP reconciliationGAAP Net cash used in operating activities -57.78M
-11.76M Purchases of property and equipment
= Free cash flow -69.54M
|
|||
| Non-GAAP gross margin non-GAAP | 67% | Q2 FY2026 | — |
|
|
|||
| Oncology tests | 104,000 | Q2 FY2026 | — |
|
|
|||
| Shield screening tests | 66,000 | Q2 FY2026 | — |
|
|
|||
| approximately 38,000 Shield screening tests | 38,000 | the three-month period ended December 31, 2025 | — |
| approximately 79,000 oncology tests | 79,000 | the three-month period ended December 31, 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GH
this stock
Guardant Health, Inc.
|
$21.92B | +56.8% | +32.9% | — | 8.5% |
|
TMO
Thermo Fisher Scientific Inc.
|
$217.80B | +1.7% | +14.5% | 31.7 | 1.3% |
|
DHR
Danaher Corp /De/
|
$147.41B | -7.6% | +8.5% | 37.2 | 1.7% |
|
NTRA
Natera, Inc.
|
$45.29B | +36.1% | -2.8% | — | 3.0% |
|
IDXX
Idexx Laboratories Inc /De
|
$44.29B | -18.2% | +10.4% | 39.5 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GH | -3.0% | +5.1% | +68.1% | -1.2% | +56.8% |
| SPY | -0.4% | +2.6% | +10.7% | +2.7% | +12.5% |
| vs SPY | -2.6% | +2.6% | +57.4% | -3.9% | +44.2% |
Key facts
CIK
1576280
CUSIP
40131M109
13F (30d)
574 filings
541 filers
Visit website
Investor relations